The research findings, published in Nature Communications, revealed the workings of a ‘hidden code’ within the genome of Human Parechovirus, a member of the Picornavirus family that includes the common cold, polio, and hand, foot and mouth disease.
The work builds on a discovery made in 2015 when scientists at the Universities of Leeds and York identified a set of encrypted signals in a plant virus with a single-stranded ribonucleic acid (RNA) genome.
This is not too dissimilar to the structure of the Parechovirus that infect humans and can cause sepsis-like illness and meningitis in children.
They found that the details of the decoding mechanism appear identical in all strains of the virus, potentially allowing a single drug to treat them all, something that is not possible with a vaccine.
Professor Reidun Twarock, a mathematical biologist at the University of York’s Departments of Mathematics, Biology, and the York Centre for Complex Systems Analysis, explained: “Previously scientists have assumed that the signals regulating the assembly of a virus were located in a unique area of the genome.
“Using a combination of biological insight and mathematical modelling, our study suggests that, by contrast, the mechanism relies on multiple dispersed sites in the genome that act together in a cooperative way to enable efficient virus formation.
“The common cold infects more than two billion people annually, making it one of the most successful viral pathogens, so we are excited to make this crucial step forward.”
Scientists had previously attempted to detect assembly signals by genetically recoding these viruses, but failed to find any.
The latest results solve this mystery; they show that the additional, ‘hidden’ code responsible for virus formation is robust against such genome changes, and is conserved across different viruses in the same family.
The team is now working to screen for potential anti-viral drugs that target this decoding mechanism. Successful future partnerships with the pharmaceutical industry and further funding support could potentially see drug development results within the next 10 years.
“We need to move away from a vaccine approach, which is what we have for flu and polio. Vaccines, although our best source of defence against polio at the moment, can result in the release of more virulent strains of the disease.
"Protecting against infection therefore relies on continued worldwide vaccination, which is both very expensive and logistically difficult.”
The World Health Organisation has a goal of eliminating polio infections worldwide via vaccination but recognises that before vaccination can be terminated there is a need to develop anti-polio drugs to cure residual infections.
Professor Sarah Butcher, from the University of Helsinki, said: “This new research means that treatment would be less likely to trigger drug resistance, which is currently one of the major problems in anti-viral therapy. This discovery could be a great leap forward in curing a host of conditions.”
The research, funded by Wellcome and is published in Nature Communications.
Professor Stockley is available for interview – contact Peter Le Riche in the University of Leeds press office on 0113 343 2049 or email firstname.lastname@example.org.
The image above shows the structure of the virus particles of human parechovirus (HPEV) and the closely related Ljungan virus. The top row shows the outside of the virus whilst the bottom row shows the inside of the virus where the RNA genome, the genetic code of the virus, is found. The images were important for the study as they show that the RNA genome, shown in red/pink, is structured within the virus. This was the first clue that the RNA genome plays an important role in the assembly of these viruses.
Steve Clapcote, Jamie Johnston, The Dunhill Medical Trust (Jun 2018), £254,874
Adrian Goldman, MRC (Jun 2018), £98,627
Darren Tomlinson, Michelle Peckham, Megan Wright, BBSRC (Jun 2018), £150,443
Simon Walker, Royal Society (Jun 2018), £337,601
Tom Thirkell, N8 Agrifood (Jun 2018), £14,870
Stephen Muench with Glaxo SmithKline & UCB Celltech, BBSRC Industrial Partnership Award (Apr 2018), £480,225
Steve Clapcote, BBSRC (Apr 2018), £443,072
Helen Miller, Innovate UK (Apr 2018), £999,960
Elisabetta Groppelli, David Rowlands & Stanley Lemon (University of North Carolina), Medical Research Foundation Fellowship (Apr 2018), £293,494
Nikesh Patel, Medical Research Foundation fellowship (Apr 2018), £290,976
Graham Askew with colleagues in Hull and Liverpool, BBSRC (Apr 2018), £150,498
Andrew Macdonald, Neil Ranson & Richard Foster, Kidney Research UK (Apr 2018), £82,821
Jessica Kwok & Ralf Richter, Leverhulme Trust (Apr 2018), £298,273
Julie Aspden, Royal Society (Apr 2018), £20,000
Liz Duncan, Royal Society (Mar 2018), £14,602
Alex O'Neill & Ryan Seipke, BBSRC (Feb 2018), £45,489
Jim Deuchars, Royal Society (Feb 2018), £16,300
Stefan Kepinski & Netta Cohen, Leverhulme Trust (Feb 2018), £320,387
Lisa Collins, BBSRC (Feb 2018), £49,950
Alison Baker, BBSRC (Feb 2018), £30,000
Lars Jeuken, BBSRC (Feb 2018), £30,000
Nikita Gamper, BBSRC (Feb 2018), £30,000
Scott Bowen, Leducq Foundation Grant (Feb 2018), £28,470
Jessica Kwok and Ronaldo Ichiyama, International Spinal Research Trust (Feb 2018), £94,450
Alex O'Neill, Oxford Drug Design (Jan 2018), £86,098
Dave Lewis and Colleagues in South Africa, HEFCE Global Challenge Research (Jan 2018), £48,000
Sarah Calaghan, Ed White, John Colyer, Isuru Jayasinghe, BHF (Jan 2018), £128,308
Christine Foyer and Alison Baker, HEFCE GCRF Grant (Jan 2018), £71,158
Alison Baker, Yun Yung Gong and Lindsay Stringer and ICRISAT India, HEFCE GCRF Grant (Jan 2018), £27,000
Graham Askew, Simon Walker, BBSRC (Jan 2018), £699,781
Jennifer Tomlinson, Royal Society (Jan 2018), £512,801
Alison Dunn, NERC (Dec 2017), £18,000
Jennifer Tomlinson, Royal Society-Research Fellows Enhancement Award (Dec 2017), £94,681
Helen Miller, AB AGri Grant (Dec 2017), £73,600
Simon Walker, Royal Society Enhancement Award (Dec 2017), £10,000
Carrie Ferguson, Bryan Taylor, Harry Rossiter, The Physiological Society (Dec 2017), £7,392
Ralf Richter, Royal Society (Dec 2017), £6,000
Christine Foyer, British Council Newton Fund (Dec 2017), £49,840
Adrian Whitehouse and colleagues in School of Chemistry and University of Liverpool, MRC (Nov 2017), £622,319
Michelle Peckham, Neil Ransom, MRC (Nov 2017), £495,159
Dave Lewis, British Council India (Nov 2017), £22,540
Elton Zeqiraj, Royal Society (Nov 2017), £15,000
Hannah Dugdale, Royal Society (Nov 2017), £15,000
Shaunna Burke, Cancer Research UK Innovation Grant (Nov 2017), £20,000
Alex O'Neill and colleagues in Chemistry, BBSRC (Nov 2017), £431,865
Jessica Kwok, Wings for Life (Nov 2017), £87,365
Tom Bennett, BBSRC (Oct 2017), £523,679
Neil Ranson, Darren Tomlinson, BBSRC (Oct 2017), £494,318
Nikita Gamper, BBSRC (Oct 2017), £490,426
Amanda Bretman and colleagues from UEA, NERC (Oct 2017), £430,886
Juan Fontana, Rosetrees Trust consumables grant (Oct 2017), £22,500
Helen Miller, DSM Nutritional Products AG (Sep 2017), £69,988
Neil Ranson, Juan Fontana, Mark Harris, Michelle Peckham, Ralf Richter, Peter Stockley, Patricija Van Oosten-Hawle and colleagues in Engineering, FMH and MAPS, Wellcome Trust Equipment Call (Sep 2017), £418,000
Jamie Johnston, Physiological Society (Sep 2017), £10,000
Frank Sobott, Adrian Goldman, Mark Harris, Andrew Macdonald, Stephen Muench, Sheena Radford and colleagues in FMH and MAPS, Wellcome Trust Equipment Call (Aug 2017), £415,000